StockData
Immix Biopharma, Inc. logo

Immix Biopharma, Inc. (IMMX) stock

IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.04−0.07 (-0.98%)

Close on Nov 19, 2026Market cap $503.64MP/E –Yield –

Immix Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Immix Biopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$39.09M. For fiscal 2025 it was -$24.66M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.66M–
FY2024Dec 31, 2024-$15.77M–
FY2023Dec 31, 2023-$11.42M–
FY2021Dec 31, 2021-$1.59M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.76M–
Q1 FY2026Mar 31, 2026-$9.86M–
Q4 FY2025Dec 31, 2025-$11.19M–
Q3 FY2025Sep 30, 2025-$6.28M–
Q2 FY2025Jun 30, 2025-$5.44M–
Q1 FY2025Mar 31, 2025-$1.75M–
Q4 FY2024Dec 31, 2024-$1.98M–
Q3 FY2024Sep 30, 2024-$4.31M–
Q2 FY2024Jun 30, 2024-$5.35M–
Q1 FY2024Mar 31, 2024-$4.13M–
Q4 FY2023Dec 31, 2023-$2.69M–
Q4 FY2021Dec 31, 2021-$1.11M–
Q3 FY2021Sep 30, 2021-$50.76K–
Q2 FY2021Jun 30, 2021-$158.01K–
Q1 FY2021Mar 31, 2021-$267.25K–

More Immix Biopharma figures

See a number that looks wrong?